Vertex Pharmaceuticals shares rose about 6% to $488.52 in premarket trading Thursday following the company's release of Phase 3 data for povetacicept, its investigational treatment for IgA nephropathy, and an announcement that it will seek U.S. regulatory approval based on those results.
In the RAINIER study, povetacicept reduced a key marker of kidney damage by 52% at 36 weeks compared with a 4.3% decline for patients receiving placebo. The trial met its primary interim endpoint, delivering a placebo-adjusted reduction in proteinuria of 49.8%.
The Phase 3 program enrolled 199 patients. At the 36-week assessment, 42% of those treated with povetacicept achieved Kidney Disease: Improving Global Outcomes - KDIGO - target proteinuria levels of less than 0.5 g/day, versus 6% in the placebo arm.
Vertex disclosed a higher incidence of upper respiratory infections in the povetacicept arm, with 18.3% of treated patients affected compared with 11.4% in the placebo group. The company also characterized the trial population as more challenging, noting participants had a longer time from diagnosis and greater use of SGLT2 inhibitors.
Market reaction was accompanied by mixed analysis from Wall Street. Barclays analysts wrote, "Though we note many expected the data to be positive, we think UPCR reduction (~50% pbo-adj) comes in at the higher end of investor expectations. We think totality of data and cross-trial comparisons suggest best-in-class efficacy."
By contrast, Baird analysts urged caution. They commented, "The Ph3 RAINIER readout of povetacicept in IgAN drove some upside in after-hours trading, but we continue to think the optimism is misplaced, with a UPCR reduction nearly identical to Otsuka’s (OTSKY, not covered) approved APRIL inhibitor, Voyxact. With Otsuka in the pole position and no meaningful differentiation for povetacicept, we continue to think there is too much hype around this program being the next major growth driver for Vertex when first and best-in-class is already out there."
The company confirmed its intent to pursue U.S. regulatory approval for povetacicept on the basis of the RAINIER results. The data package and regulatory timeline were not further detailed in the company announcement.
Market and sector context
The RAINIER readout touches both clinical and commercial considerations for the kidney disease treatment landscape. Proteinuria reduction and KDIGO target attainment are central efficacy measures for therapies in IgA nephropathy, and safety signals such as increased upper respiratory infections are important inputs for regulatory review and prescribing decisions. The trial's characterization as a more challenging population may also factor into interpretations of efficacy versus prior studies.